Pfizer (PFE)

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies stack up for investors this year.

This little-discussed pipeline program could prove to be a big success.

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such a...

Businesses with strong free cash flow tend to be more adaptable and resilient. Some of these companies shine bright by using their cash wisely to strengthen ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

Pfizer said Sunday its Braftovi-tied regimen nearly doubled the time colon cancer patients lived without getting sicker.

Why do so many people feel overwhelmed right now? And what can investors do about it?

Often, investors and Wall Street analysts focus on the short term and don't give enough thought to the long term.

The most recent research report on the "Addiction Treatment Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts

Pfizer and Innovent Biologics sign a $10.5 billion cancer drug deal to develop 12 oncology programs globally.

The most recent research report on the "Rituxan (rituximab) Drug Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore

The most recent research report on the "Drugs for Oral Mucositis Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic fore

Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...

Explore how two quantum innovators stack up on customer reach, financial health, and risk as they race for commercial leadership in a fast-evolving sector.

These three dividend stocks combine strong yields with resilient businesses.

The Dow is no longer dominated by industrial, energy, manufacturing, and consumer goods companies.

The payout ratio is over 100% for this high-yield healthcare giant, but don't run for the hills just yet.

As with other pharma companies, much rides on Pfizer's pipeline; it has many promising formulations in late-stage trials.

The pharma giant is taking steps to expand its portfolio.

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, incl...

These healthcare giants have been top dividend stocks for years, and both could be intriguing options to consider right now.

Relay Therapeutics, a clinical-stage biotech, is getting a boost after positive trial news for its lead therapy.

Down more than 50% from its 2021 highs, this pharmaceutical giant has been forgotten by Wall Street.

The most recent research report on the "Pediatrics Medicine Market"covering the years 2026 to 2035, provides in-depth analysis, accurate economic forecasts